Bexarotene is a novel retinoid agent that has demonstrated substantial clinical activity against CTCL.[ 1 鈥 4 ] However, its precise mechanism of action in this disease remains to be elucidated. Bexarotene is known to produce alterations in cellular growth, proliferation, differentiation and ...
1. Gniadecki R. An oral retinoid (bexarotene) in cutaneous T-cell lymphoma: mechanism of action and clinical application. Int J Dermatol. 2007;46(1):17-23. 2. ACCORD STAMP Investigators. Smith MR. Bexarotene in advanced cutaneous T-cell lymphoma: results of a phase III randomized, double...
Bexarotene is available in 75-mg capsules for oral administrationin the treatment of refractory cutaneous T-cell lymphoma.The agent is also available as a gel that may be usedtopically. The mechanism of action has not been fully establishedbut is thought to involve binding to retinoid receptorsres...
The mechanism of action has not been fully establishedbut is thought to involve binding to retinoid receptorsresulting ultimately in the formation of transcription factorsthat promote cell differentiation and regulate cellular proliferation.168 Bexarotene has been demonstrated to activateapoptosis as a result...
Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown. Therapeutic ...
retinoid X receptor (RXR) agonist used as an antineoplastic.参考文献:[1]. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res.2002 May;8(5):1234-40.
In patients usinginsulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting inhypoglycemia. Hypoglycemia has not been associated with the...
Bexarotene is a novel retinoid agent that has demonstrated substantial clinical activity against CTCL.[ 1 – 4 ] However, its precise mechanism of action in this disease remains to be elucidated. Bexarotene is known to produce alterations in cellular growth, proliferation, differentiation and ...
68 Bexatotene's mechanism of action in CTCL is not known, although RXR agonists have been shown to modulate growth and differentiation and apoptosis in a variety of cellular systems 69-71 and to interact with intracellular signaling pathways and transcription factors.47,72 Isotretinoin and et...
Kong Bo, Wang Li, Chiang JYL, Zhang Y, Klaassen CD, Guo GL (2012) Mechanism of tissue-specific farnesoid x receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56(3):1034–1043 ArticleCASPubMedGoogle Scholar ...